Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014, Article ID 608930, 16 pages
http://dx.doi.org/10.1155/2014/608930
Review Article

Cysteinyl Leukotriene Receptor-1 Antagonists as Modulators of Innate Immune Cell Function

1Medical Research Council Unit for Inflammation and Immunity, Department of Immunology, Faculty of Health Sciences, University of Pretoria, P.O. Box 2034, Pretoria 0001, South Africa
2Tshwane Academic Division of the National Health Laboratory Service, Pretoria 0001, South Africa
3Division of Pulmonology, Department of Internal Medicine, Charlotte Maxeke Johannesburg Academic Hospital and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa

Received 15 January 2014; Revised 9 May 2014; Accepted 12 May 2014; Published 25 May 2014

Academic Editor: Mónica Vermeulen

Copyright © 2014 A. J. Theron et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Peters-Golden and W. R. Henderson Jr., “Mechanisms of disease: leukotrienes,” The New England Journal of Medicine, vol. 357, no. 18, pp. 1798–1854, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Okunishi and M. Peters-Golden, “Leukotrienes and airway inflammation,” Biochimica et Biophysica Acta, vol. 1810, no. 11, pp. 1096–1102, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. J. P. Scott and M. Peters-Golden, “Antileukotriene agents for the treatment of lung disease,” American Journal of Respiratory and Critical Care Medicine, vol. 188, no. 5, pp. 538–544, 2013. View at Google Scholar
  4. S. Amlani, T. Nadarajah, and R. A. McIvor, “Montelukast for the treatment of asthma in the adult population,” Expert Opinion on Pharmacotherapy, vol. 12, no. 13, pp. 2119–2128, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Pacheco, N. Freymond, and G. Devouassoux, “Impact of montelukast on asthma associated with rhinitis, and other triggers and co-morbidities,” Journal of Asthma, vol. 51, no. 1, pp. 1–17, 2014. View at Google Scholar
  6. D. C. Kim, F. I. Hsu, N. A. Barrett et al., “Cysteinyl leukotrienes regulate Th2 cell-dependent pulmonary inflammation,” The Journal of Immunology, vol. 176, no. 7, pp. 4440–4448, 2006. View at Google Scholar · View at Scopus
  7. Y. Jiang, Y. Kanaoka, C. Feng, K. Nocka, S. Rao, and J. A. Boyce, “Cutting edge: Interleukin 4-dependent mast cell proliferation requires autocrine/intracrine cysteinyl leukotriene-induced signaling,” The Journal of Immunology, vol. 177, no. 5, pp. 2755–2759, 2006. View at Google Scholar · View at Scopus
  8. V. Kondeti, E. Duah, N. Al-Azzam, C. K. Thodeti, J. A. Boyce, and S. Paruchuri, “Differential regulation of cysteinyl leukotriene receptor signaling by protein kinase C in human mast cells,” PLoS ONE, vol. 8, no. 8, Article ID e71536, 2013. View at Google Scholar
  9. C. H. C. Serezani, D. M. Aronoff, S. Jancar, P. Mancuso, and M. Peters-Golden, “Leukotrienes enhance the bactericidal activity of alveolar macrophages against Klebsiella pneumoniae through the activation of NADPH oxidase,” Blood, vol. 106, no. 3, pp. 1067–1075, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Ichiyama, M. Kajimoto, M. Hasegawa, K. Hashimoto, T. Matsubara, and S. Furukawa, “Cysteinyl leukotrienes enhance tumour necrosis factor-α-induced matrix metalloproteinase-9 in human monocytes/macrophages,” Clinical & Experimental Allergy, vol. 37, no. 4, pp. 608–614, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Woszczek, L.-Y. Chen, S. Nagineni et al., “Leukotriene D4 induces gene expression in human monocytes through cysteinyl leukotriene type I receptor,” Journal of Allergy & Clinical Immunology, vol. 121, no. 1, pp. 215–221, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Hashimoto, T. Ichiyama, M. Hasegawa, S. Hasegawa, T. Matsubara, and S. Furukawa, “Cysteinyl leukotrienes induce monocyte chemoattractant protein-1 in human monocyte/macrophages via mitogen-activated protein kinase and nuclear factor-κb pathways,” International Archives of Allergy and Immunology, vol. 149, no. 3, pp. 275–282, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Ichiyama, M. Hasegawa, K. Hashimoto, T. Matsushige, R. Hirano, and S. Furukawa, “Cysteinyl leukotrienes induce macrophage inflammatory protein-1 in human monocytes/macrophages,” International Archives of Allergy and Immunology, vol. 148, no. 2, pp. 147–153, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Thompson, A. Cloutier, Y. Bossé et al., “CysLT1 receptor engagement induces activator protein-1- and NF-κB-dependent IL-8 expression,” American Journal of Respiratory Cell and Molecular Biology, vol. 35, no. 6, pp. 697–704, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Poulin, C. Thompson, M. Thivierge et al., “Cysteinyl-leukotrienes induce vascular endothelial growth factor production in human monocytes and bronchial smooth muscle cells,” Clinical & Experimental Allergy, vol. 41, no. 2, pp. 204–217, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Haneda, S. Hasegawa, R. Hirano, K. Hashimoto, A. Ohsaki, and T. Ichiyama, “Leukotriene D4 enhances tumor necrosis factor-α-induced vascular endothelial growth factor production in human monocytes/macrophages,” Cytokine, vol. 55, no. 1, pp. 24–28, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Fregonese, M. Silvestri, F. Sabatini, and G. A. Rossi, “Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT1 receptor-mediated mechanism,” Clinical & Experimental Allergy, vol. 32, no. 5, pp. 745–750, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Y. Meliton, N. M. Munoz, and A. R. Leff, “Blockade of avidity and focal clustering of β2-integrin by cysteinyl leukotriene antagonism attenuates eosinophil adhesion,” Journal of Allergy & Clinical Immunology, vol. 120, no. 6, pp. 1316–1323, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Mori, Y. Takaku, T. Kobayashi, K. Hagiwara, M. Kanazawa, and M. Nagata, “Eosinophil superoxide anion generation induced by adhesion molecules and leukotriene D4,” International Archives of Allergy and Immunology, vol. 149, no. 1, pp. 31–38, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. J. S. Neves, A. L. Radke, and P. F. Weller, “Cysteinyl leukotrienes acting via granule membrane-expressed receptors elicit secretion from within cell-free human eosinophil granules,” Journal of Allergy & Clinical Immunology, vol. 125, no. 2, pp. 477–482, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Itagaki, B. E. Barton, T. F. Murphy et al., “Eicosanoid-induced store-operated calcium entry in dendritic cells,” Journal of Surgical Research, vol. 169, no. 2, pp. 301–310, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. I. Machida, H. Matsuse, Y. Kondo et al., “Cysteinyl leukotrienes regulate dendritic cell functions in a murine model of asthma,” The Journal of Immunology, vol. 172, no. 3, pp. 1833–1838, 2004. View at Google Scholar · View at Scopus
  23. M. Heimbürger and J. E. Palmblad, “Effects of leukotriene C4 and D4, histamine and bradykinin on cytosolic calcium concentrations and adhesiveness of endothelial cells and neutrophils,” Clinical & Experimental Immunology, vol. 103, no. 3, pp. 454–460, 1996. View at Google Scholar
  24. G. Lärfars, F. Lantoine, M.-A. Devynck, J. Palmblad, and H. Gyllenhammar, “Activation of nitric oxide release and oxidative metabolism by leukotrienes B4, C4, and D4 in human polymorphonuclear leukocytes,” Blood, vol. 93, no. 4, pp. 1399–1405, 1999. View at Google Scholar · View at Scopus
  25. A. J. Theron, C. M. Gravett, H. C. Steel, G. R. Tintinger, C. Feldman, and R. Anderson, “Leukotrienes C4 and D4 sensitize human neutrophils for hyperreactivity to chemoattractants,” Inflammation Research, vol. 58, no. 5, pp. 263–268, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Anderson, A. J. Theron, C. M. Gravett, H. C. Steel, G. R. Tintinger, and C. Feldman, “Montelukast inhibits neutrophil pro-inflammatory activity by a cyclic AMP-dependent mechanism,” British Journal of Pharmacology, vol. 156, no. 1, pp. 105–115, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Cheng, J. A. Leff, R. Amin et al., “Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females,” Pharmaceutical Research, vol. 13, no. 3, pp. 445–448, 1996. View at Google Scholar
  28. B. Knorr, H. H. Nguyen, G. L. Kearns et al., “Montelukast dose selection in children ages 2 to 5 years: comparison of population pharmacokinetics between children and adults,” The Journal of Clinical Pharmacology, vol. 41, no. 6, pp. 612–619, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. G. R. Tintinger, C. Feldman, A. J. Theron, and R. Anderson, “Montelukast: more than a cysteinyl leukotriene receptor antagonist?” TheScientificWorldJournal, vol. 10, pp. 2403–2413, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Ramires, M. F. Caiaffa, A. Tursi, J. Z. Haeggström, and L. Macchia, “Novel inhibitory effect on 5-lipoxygenase activity by the anti-asthma drug montelukast,” Biochemical and Biophysical Research Communications, vol. 324, no. 2, pp. 815–821, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Woszczek, L.-Y. Chen, S. Alsaaty, S. Nagineni, and J. H. Shelhamer, “Concentration-dependent noncysteinyl leukotriene type 1 receptor-mediated inhibitory activity of leukotriene receptor antagonists,” The Journal of Immunology, vol. 184, no. 4, pp. 2219–2225, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Fogli, F. Stefanelli, A. Martelli et al., “Protective effect of high-dose montelukast on salbutamol-induced homologous desensitisation in airway smooth muscle,” Pulmonary Pharmacology & Therapeutics, vol. 26, no. 6, pp. 693–699, 2013. View at Publisher · View at Google Scholar
  33. C. H. Serezani, M. N. Ballinger, D. M. Aronoff, and M. Peters-Golden, “Cyclic AMP: master regulator of innate immune cell function,” American Journal of Respiratory Cell and Molecular Biology, vol. 39, no. 2, pp. 127–132, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Fogli, F. Stefanelli, T. Neri et al., “Montelukast prevents microparticle-induced inflammatory and functional alterations in human bronchial smooth muscle cells,” Pharmacological Research, vol. 76, pp. 149–156, 2013. View at Google Scholar
  35. F. Tahan, E. Jazrawi, T. Moodley, G. E. Rovati, and I. M. Adcock, “Montelukast inhibits tumour necrosis factor-α-mediated interleukin-8 expression through inhibition of nuclear factor-κB p65-associated histone acetyltransferase activity,” Clinical & Experimental Allergy, vol. 38, no. 5, pp. 805–811, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. G. C. Parry and N. Mackman, “Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NFkappaB-mediated transcription,” The Journal of Immunology, vol. 159, no. 11, pp. 5450–5456, 1997. View at Google Scholar
  37. A. S. Kahnt, R. Rörsch, O. Diehl et al., “Cysteinyl leukotriene-receptor-1 antagonists interfere with PGE2 synthesis by inhibiting mPGES-1 activity,” Biochemical Pharmacology, vol. 86, no. 2, pp. 286–296, 2013. View at Google Scholar
  38. A. J. Robinson, D. Kashanin, F. O'Dowd, V. Williams, and G. M. Walsh, “Montelukast inhibition of resting and GM-CSF-stimulated eosinophil adhesion to VCAM-1 under flow conditions appears independent of cysLT1R antagonism,” Journal of Leukocyte Biology, vol. 83, no. 6, pp. 1522–1529, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Langlois, C. Ferland, G. M. Tremblay, and M. Laviolette, “Montelukast regulates eosinophil protease activity through a leukotriene-independent mechanism,” Journal of Allergy & Clinical Immunology, vol. 118, no. 1, pp. 113–119, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. C. M. Gravett, A. J. Theron, H. C. Steel et al., “Interactive inhibitory effects of formoterol and montelukast on activated human neutrophils,” European Respiratory Journal, vol. 36, no. 6, pp. 1417–1424, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. N. Flamand, M. E. Surette, S. Picard, S. Bourgoin, and P. Borgeat, “Cyclic AMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils,” Molecular Pharmacology, vol. 62, no. 2, pp. 250–256, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Savari, M. Liu, Y. Zhang, W. Sime, and A. Sjölander, “CysLT1R antagonists inhibit tumor growth in a xenograft model of colon cancer,” PLoS ONE, vol. 8, no. 9, Article ID e73466, 2013. View at Google Scholar
  43. N. Pathomthongtaweechai, S. Soodvilai, V. Chatsudthipong, and C. Muanprasat, “Pranlukast inhibits renal epithelial cyst progression via activation of AMP-activated protein kinase,” European Journal of Pharmacology, vol. 724, pp. 67–76, 2014. View at Google Scholar
  44. J. M. Cacicedo, N. Yagihashi, J. F. Keaney Jr., N. B. Ruderman, and Y. Ido, “AMPK inhibits fatty acid-induced increases in NF-κB transactivation in cultured human umbilical vein endothelial cells,” Biochemical and Biophysical Research Communications, vol. 324, no. 4, pp. 1204–1209, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. G. R. Tintinger, H. C. Steel, and R. Anderson, “Taming the neutrophil: calcium clearance and influx mechanisms as novel targets for pharmacological control,” Clinical & Experimental Immunology, vol. 141, no. 2, pp. 191–200, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. G. R. Tintinger, H. C. Steel, A. J. Theron, and R. Anderson, “Pharmacological control of neutrophil-mediated inflammation: strategies targeting calcium handling by activated polymorphonuclear leukocytes,” Drug Design, Development and Therapy, no. 2, pp. 95–104, 2008. View at Google Scholar · View at Scopus
  47. H. Holmsen, E. Storm, and H. J. Day, “Determination of ATP and ADP in blood platelets: a modification of the firefly luciferase assay for plasma,” Analytical Biochemistry, vol. 46, no. 2, pp. 489–501, 1972. View at Google Scholar · View at Scopus
  48. A. Nayak, “A review of montelukast in the treatment of asthma and allergic rhinitis,” Expert Opinion on Pharmacotherapy, vol. 5, no. 3, pp. 679–686, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. G. Riccioni, T. Bucciarelli, B. Mancini, C. di Ilio, and N. D'Orazio, “Antileukotriene drugs: clinical application, effectiveness and safety,” Current Medicinal Chemistry, vol. 14, no. 18, pp. 1966–1977, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. D. T. Scow, G. K. Luttermoser, and K. S. Dickerson, “Leukotriene inhibitors in the treatment of allergy and asthma,” American Family Physician, vol. 75, no. 1, pp. 65–70, 2007. View at Google Scholar · View at Scopus
  51. J. Grainger and A. Drake-Lee, “Montelukast in allergic rhinitis: a systematic review and meta-analysis,” Clinical Otolaryngology, vol. 31, no. 5, pp. 360–367, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Nayak and R. B. Langdon, “Montelukast in the treatment of allergic rhinitis: an evidence-based review,” Drugs, vol. 67, no. 6, pp. 887–901, 2007. View at Google Scholar · View at Scopus
  53. N. Sardana, C. Santos, E. Lehman, and T. Craig, “A comparison of intranasal corticosteroid, leukotriene receptor antagonist, and topical antihistamine in reducing symptoms of perennial allergic rhinitis as assessed through the rhinitis severity score,” Allergy and Asthma Proceedings, vol. 31, no. 1, pp. 5–9, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Ciebiada, M. Gorska-Ciebiada, M. Barylski, T. Kmiecik, and P. Gorski, “Use of montelukast alone or in combination with desloratadine or levocetirizine in patients with persistent allergic rhinitis,” American Journal of Rhinology and Allergy, vol. 25, no. 1, pp. e1–e6, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. K. Okubo and K. Baba, “A double-blind non-inferiority clinical study of montelukast, a cysteinyl leukotriene receptor 1 antagonist, compared with pranlukast in patients with seasonal allergic rhinitis,” Allergology International, vol. 57, no. 4, pp. 383–390, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. S. E. Wenzel, “The role of leukotrienes in asthma,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 69, no. 2-3, pp. 145–155, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. M. S. Kavuru, R. Subramony, and A. R. Vann, “Antileukotrienes and asthma: alternative or adjunct to inhaled steroids?” Cleveland Clinic Journal of Medicine, vol. 65, no. 10, pp. 519–526, 1998. View at Google Scholar · View at Scopus
  58. L. García-Marcos, A. Schuster, and E. G. Pérez-Yarza, “Benefit-risk assessment of antileukotrienes in the management of asthma,” Drug Safety, vol. 26, no. 7, pp. 483–518, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. S. P. Peters, “Leukotriene receptor antagonists in asthma therapy,” Journal of Allergy & Clinical Immunology, vol. 111, no. 1, pp. S62–S70, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. R. Polosa, “Critical appraisal of antileukotriene use in asthma management,” Current Opinion in Pulmonary Medicine, vol. 13, no. 1, pp. 24–30, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. P. M. O'Byrne, G. M. Gauvreau, and D. M. Murphy, “Efficacy of leukotriene receptor antagonists and synthesis inhibitors in asthma,” Journal of Allergy & Clinical Immunology, vol. 124, no. 3, pp. 397–403, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. P. Montuschi and M. L. Peters-Golden, “Leukotriene modifiers for asthma treatment,” Clinical & Experimental Allergy, vol. 40, no. 12, pp. 1732–1741, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. P. Montuschi, “Role of leukotrienes and leukotriene modifiers in asthma,” Pharmaceuticals, vol. 3, no. 6, pp. 1792–1811, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. K. V. Blake, “Montelukast: data from clinical trials in the management of asthma,” Annals of Pharmacotherapy, vol. 33, no. 12, pp. 1299–1314, 1999. View at Google Scholar · View at Scopus
  65. B. Jarvis and A. Markham, “Montelukast: a review of its therapeutic potential in persistent asthma,” Drugs, vol. 59, no. 4, pp. 891–928, 2000. View at Google Scholar · View at Scopus
  66. P. Paggiaro and E. Bacci, “Montelukast in asthma: a review of its efficacy and place in therapy,” Therapeutic Advances in Chronic Disease, vol. 2, no. 1, pp. 47–58, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. J.-J. Tsai, S.-C. Chan, C.-K. Ho, Y.-C. Su, and T.-C. Feng, “Efficacy of zafirlukast in the treatment of patients with bronchial asthma,” Journal of Microbiology, Immunology and Infection, vol. 34, no. 1, pp. 63–70, 2001. View at Google Scholar · View at Scopus
  68. C. J. Dunn and K. L. Goa, “Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma,” Drugs, vol. 61, no. 2, pp. 285–315, 2001. View at Google Scholar · View at Scopus
  69. G. Riccioni, M. Castronuovo, M. de Benedictis et al., “Zafirlukast versus budesonide on bronchial reactivity in subjects with mild-persistent asthma,” International Journal of Immunopathology and Pharmacology, vol. 14, no. 2, pp. 87–92, 2001. View at Google Scholar · View at Scopus
  70. C.-J. Huang, C.-H. Wang, W.-T. Liu et al., “Zafirlukast improves pulmonary function in patients with moderate persistent asthma receiving regular inhaled steroids: a prospective randomized control study,” Chang Gung Medical Journal, vol. 26, no. 8, pp. 554–560, 2003. View at Google Scholar · View at Scopus
  71. R. A. Silverman, R. M. Nowak, P. E. Korenblat et al., “Zafirlukast treatment for acute asthma: evaluation in a randomized, double-blind, multicenter trial,” Chest, vol. 126, no. 5, pp. 1480–1489, 2004. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Tomari, T. Shimoda, T. Kawano et al., “Effects of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, combined with inhaled beclomethasone in patients with moderate or severe asthma,” Annals of Allergy, Asthma & Immunology, vol. 87, no. 2, pp. 156–161, 2001. View at Google Scholar · View at Scopus
  73. S. J. Keam, K. A. Lyseng-Williamson, K. L. Goa et al., “Pranlukast: a review of its use in the management of asthma,” Drugs, vol. 63, no. 10, pp. 991–1019, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. T. Niitsuma, J. Izawa, N. Maruoka et al., “Clinical evaluation of response to long-term treatment with Pranlukast in patients with bronchial asthma,” Journal of Investigational Allergology and Clinical Immunology, vol. 14, no. 4, pp. 284–291, 2004. View at Google Scholar · View at Scopus
  75. H. Yanagawa, A. Sugita, M. Azuma et al., “Long-term follow-up of pulmonary function in bronchial asthma patients treated with pranlukast,” Lung, vol. 182, no. 1, pp. 51–58, 2004. View at Publisher · View at Google Scholar · View at Scopus
  76. T. Horiguchi, S. Tachikawa, R. Kondo et al., “Comparative evaluation of the leukotriene receptor antagonist pranlukast versus the steroid inhalant fluticasone in the therapy of aged patients with mild bronchial asthma,” Arzneimittel-Forschung, vol. 57, no. 2, pp. 87–91, 2007. View at Google Scholar · View at Scopus
  77. H. Ohbayashi, N. Shibata, T. Hirose, and M. Adachi, “Additional effects of pranlukast in salmeterol/fluticasone combination therapy for the asthmatic distal airway in a randomized crossover study,” Pulmonary Pharmacology & Therapeutics, vol. 22, no. 6, pp. 574–579, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. H. Yasui, T. Fujisawa, N. Inui et al., “Impact of add-on pranlukast in stable asthma; the additive effect on peripheral airway inflammation,” Respiratory Medicine, vol. 106, no. 4, pp. 508–514, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. A. M. Vignola, “Effects of inhaled corticosteroids, leukotriene receptor antagonists, or both, plus long-acting β2-agonists on asthma pathophysiology: a review of the evidence,” Drugs, vol. 63, no. 2, pp. 35–51, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. D. Price, S. D. Musgrave, L. Shepstone et al., “Leukotriene antagonists as first-line or add-on asthma-controller therapy,” The New England Journal of Medicine, vol. 364, no. 18, pp. 1695–1707, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. P. S. Creticos, “Treatment options for initial maintenance therapy of persistent asthma: a review of inhaled corticosteroids and leukotriene receptor antagonists,” Drugs, vol. 63, no. 2, pp. 1–20, 2003. View at Google Scholar · View at Scopus
  82. B. F. Chauhan and F. M. Ducharme, “Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children,” Cochrane Database of Systematic Reviews, vol. 5, p. CD002314, 2012. View at Google Scholar · View at Scopus
  83. F. M. Ducharme, “Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence,” British Medical Journal, vol. 324, no. 7353, pp. 1545–1548, 2002. View at Google Scholar · View at Scopus
  84. F. S. Ram, C. J. Cates, and F. M. Ducharme, “Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma,” Cochrane Database of Systematic Reviews, vol. 4, no. 1, p. CD003137, 2005. View at Google Scholar · View at Scopus
  85. S. Joos, A. Miksch, J. Szecsenyi et al., “Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review,” Thorax, vol. 63, no. 5, pp. 453–462, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. B. J. Lipworth and C. M. Jackson, “Second-line controller therapy for persistent asthma uncontrolled on inhaled corticosteroids,” Drugs, vol. 62, no. 16, pp. 2315–2332, 2002. View at Google Scholar · View at Scopus
  87. P. J. Helms, “Corticosteroid-sparing options in the treatment of childhood asthma,” Drugs, vol. 59, no. 1, pp. 15–22, 2000. View at Google Scholar · View at Scopus
  88. H. Bisgaard, “Leukotriene modifiers in pediatric asthma management,” Pediatrics, vol. 107, no. 2, pp. 381–390, 2001. View at Publisher · View at Google Scholar · View at Scopus
  89. B. Knorr, L. M. Franchi, H. Bisgaard et al., “Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years,” Pediatrics, vol. 108, no. 3, p. E48, 2001. View at Google Scholar · View at Scopus
  90. J. E. Spahr and M. Krawiec, “Leukotriene receptor antagonists—risks and benefits for use in paediatric asthma,” Expert Opinion on Drug Safety, vol. 3, no. 3, pp. 173–185, 2004. View at Publisher · View at Google Scholar · View at Scopus
  91. U. Wahn and S. B. Dass, “Review of recent results of montelukast use as a monotherapy in children with mild asthma,” Clinical Therapeutics, vol. 30, no. 1, pp. 1026–1035, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. M. M. del Giudice, A. Pezzulo, C. Capristo et al., “Leukotriene modifiers in the treatment of asthma in children,” Therapeutic Advances in Respiratory Disease, vol. 3, no. 5, pp. 245–251, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. C. M. Gravett, G. R. Tintinger, A. J. Theron, R. Anderson, C. Feldman, and R. Green, “Montelukast sodium: administration to children to control intermittent asthma,” Clinical Medicine Reviews in Therapeutics, vol. 2, no. 1, pp. 1–10, 2010. View at Google Scholar
  94. S. Amlani and R. A. McIvor, “Montelukast in childhood asthma: what is the evidence for its use?” Expert Review of Respiratory Medicine, vol. 5, no. 1, pp. 17–25, 2011. View at Publisher · View at Google Scholar · View at Scopus
  95. C. Dumitru, S. M. H. Chan, and V. Turcanu, “Role of leukotriene receptor antagonists in the management of pediatric asthma,” Pediatric Drugs, vol. 14, no. 5, pp. 317–330, 2012. View at Publisher · View at Google Scholar · View at Scopus
  96. K. Massingham, S. Fox, and A. Smaldone, “Asthma therapy in pediatric patients: a systematic review of treatment with montelukast versus inhaled corticosteroids,” Journal of Pediatric Health Care, vol. 28, no. 1, pp. 51–62, 2014. View at Publisher · View at Google Scholar · View at Scopus
  97. A. Bozek, B. Warkocka-Szoltysek, A. Filipowska-Gronska, and J. Jarzab, “Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients,” Journal of Asthma, vol. 49, no. 5, pp. 530–534, 2012. View at Publisher · View at Google Scholar · View at Scopus
  98. N. Scichilone, S. Battaglia, A. Benfante, and V. Bellia, “Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients,” Clinical Interventions in Aging, vol. 8, pp. 1329–1337, 2013. View at Google Scholar
  99. E. O. Meltzer, “Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of 'one linked airway disease',” Annals of Allergy, Asthma & Immunology, vol. 84, no. 2, pp. 176–187, 2000. View at Google Scholar · View at Scopus
  100. J. C. Virchow and C. Bachert, “Efficacy and safety of montelukast in adults with asthma and allergic rhinitis,” Respiratory Medicine, vol. 100, no. 11, pp. 1952–1959, 2006. View at Publisher · View at Google Scholar · View at Scopus
  101. E. Valovirta, “Managing co-morbid asthma with allergic rhinitis: targeting the one-airway with leukotriene receptor antagonists,” World Allergy Organization Journal, vol. 5, no. 3, pp. S210–S211, 2012. View at Publisher · View at Google Scholar · View at Scopus
  102. G. Piatti, L. Ceriotti, G. Cavallaro et al., “Effects of zafirlukast on bronchial asthma and allergic rhinitis,” Pharmacological Research, vol. 47, no. 6, pp. 541–547, 2003. View at Publisher · View at Google Scholar · View at Scopus
  103. C. A. Camargo Jr., D. M. Gurner, H. A. Smithline et al., “A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma,” Journal of Allergy & Clinical Immunology, vol. 125, no. 2, pp. 374–380, 2010. View at Publisher · View at Google Scholar · View at Scopus
  104. T. S. Hallstrand and W. R. Henderson Jr., “The evolving role of intravenous leukotriene modifiers in acute asthma,” Journal of Allergy & Clinical Immunology, vol. 125, no. 2, pp. 381–382, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. M. Adachi, H. Taniguchi, Y. Tohda et al., “The efficacy and tolerability of intravenous montelukast in acute asthma exacerbations in japanese patients,” Journal of Asthma, vol. 49, no. 6, pp. 649–656, 2012. View at Publisher · View at Google Scholar · View at Scopus
  106. C. R. Morris, A. B. Becker, A. Piñeiro et al., “A randomized, placebo-controlled study of intravenous montelukast in children with acute asthma,” Annals of Allergy, Asthma & Immunology, vol. 104, no. 2, pp. 161–171, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. C. F. Ramsay, D. Pearson, S. Mildenhall, and A. M. Wilson, “Oral montelukast in acute asthma exacerbations: a randomised, double-blind, placebo-controlled trial,” Thorax, vol. 66, no. 1, pp. 7–11, 2011. View at Publisher · View at Google Scholar · View at Scopus
  108. A. B. S. Zubairi, N. Salahuddin, A. Khawaja et al., “A randomized, double-blind, placebo-controlled trial of oral montelukast in acute asthma exacerbation,” BMC Pulmonary Medicine, vol. 13, no. 1, article 20, 2013. View at Publisher · View at Google Scholar · View at Scopus
  109. V. K. Todi, R. Lodha, and S. K. Kabra, “Effect of addition of single dose of oral montelukast to standard treatment in acute moderate to severe asthma in children between 5 and 15 years of age: a randomised, double-blind, placebo controlled trial,” Archives of Disease in Childhood, vol. 95, no. 7, pp. 540–543, 2010. View at Publisher · View at Google Scholar · View at Scopus
  110. A. Capsomidis and M. Tighe, “Is oral montelukast beneficial in treating acute asthma exacerbations in children?” Archives of Disease in Childhood, vol. 95, no. 11, pp. 948–950, 2010. View at Publisher · View at Google Scholar · View at Scopus
  111. O. M. P. Jolobe, “Oral montelukast may have a role in severe and in life-threatening acute asthma,” Archives of Disease in Childhood, vol. 96, no. 3, p. 322, 2011. View at Publisher · View at Google Scholar · View at Scopus
  112. K. Watts and R. J. P. G. Chavasse, “Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children,” Cochrane Database of Systematic Reviews, vol. 5, p. CD006100, 2012. View at Google Scholar · View at Scopus
  113. D. Price, T. A. Popov, L. Bjermer et al., “Effect of montelukast for treatment of asthma in cigarette smokers,” Journal of Allergy & Clinical Immunology, vol. 131, no. 3, pp. 763–771, 2013. View at Publisher · View at Google Scholar · View at Scopus
  114. G. Braganza, R. Chaudhuri, and N. C. Thomson, “Treating patients with respiratory disease who smoke,” Therapeutic Advances in Respiratory Disease, vol. 2, no. 2, pp. 95–107, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. J. P. Kemp, R. J. Dockhorn, G. G. Shapiro et al., “Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma,” Journal of Pediatrics, vol. 133, no. 3, pp. 424–428, 1998. View at Publisher · View at Google Scholar · View at Scopus
  116. W. W. Busse, K. A. McGill, and R. J. Horwitz, “Leukotriene pathway inhibitors in asthma and chronic obstructive pulmonary disease,” Clinical & Experimental Allergy, vol. 29, no. 2, pp. 110–115, 1999. View at Google Scholar · View at Scopus
  117. L. Mastalerz, A. Gawlewicz-Mroczka, E. Nizankowska, A. Cmiel, and A. Szczeklik, “Protection against exercise-induced bronchoconstriction by montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma,” Clinical & Experimental Allergy, vol. 32, no. 9, pp. 1360–1365, 2002. View at Publisher · View at Google Scholar · View at Scopus
  118. R. A. Tan and S. L. Spector, “Exercise-induced asthma: diagnosis and management,” Annals of Allergy, Asthma & Immunology, vol. 89, no. 3, pp. 226–297, 2002. View at Google Scholar · View at Scopus
  119. S. D. Anderson, “Single-dose agents in the prevention of exercise-induced asthma: a descriptive review,” Treatments in Respiratory Medicine, vol. 3, no. 6, pp. 365–379, 2004. View at Publisher · View at Google Scholar · View at Scopus
  120. J. P. Parsons and J. G. Mastronarde, “Exercise-induced bronchoconstriction in athletes,” Chest, vol. 128, no. 6, pp. 3966–3974, 2005. View at Publisher · View at Google Scholar · View at Scopus
  121. F. M. de Benedictis, S. Vaccher, and D. de Benedictis, “Montelukast sodium for exercise-induced asthma,” Drugs of Today, vol. 44, no. 11, pp. 845–855, 2008. View at Publisher · View at Google Scholar · View at Scopus
  122. T. Grzelewski and I. Stelmach, “Exercise-induced bronchoconstriction in asthmatic children: a comparative systematic review of the available treatment options,” Drugs, vol. 69, no. 12, pp. 1533–1553, 2009. View at Publisher · View at Google Scholar · View at Scopus
  123. J. P. Parsons and J. G. Mastronarde, “Exercise-induced asthma,” Current Opinion in Pulmonary Medicine, vol. 15, no. 1, pp. 25–28, 2009. View at Publisher · View at Google Scholar · View at Scopus
  124. M. Duong, R. Amin, A. J. Baatjes et al., “The effect of montelukast, budesonide alone, and in combination on exercise-induced bronchoconstriction,” Journal of Allergy & Clinical Immunology, vol. 130, no. 2, pp. 535–539, 2012. View at Publisher · View at Google Scholar · View at Scopus
  125. B. Dahlén, “Treatment of aspirin-intolerant asthma with antileukotrienes,” American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 2, part 2, pp. S137–S141, 2000. View at Google Scholar · View at Scopus
  126. S.-E. Dahlén, K. Malmström, E. W. A. Nizankowska et al., “Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial,” American Journal of Respiratory and Critical Care Medicine, vol. 165, no. 1, pp. 9–14, 2002. View at Google Scholar · View at Scopus
  127. J. B. Usery, T. H. Self, M. P. Muthiah, and C. K. Finch, “Potential role of leukotriene modifiers in the treatment of chronic obstructive pulmonary disease,” Pharmacotherapy, vol. 28, no. 9, pp. 1183–1187, 2008. View at Publisher · View at Google Scholar · View at Scopus
  128. P. Celik, A. Sakar, Y. Havlucu, H. Yuksel, P. Turkdogan, and A. Yorgancioglu, “Short-term effects of montelukast in stable patients with moderate to severe COPD,” Respiratory Medicine, vol. 99, no. 4, pp. 444–450, 2005. View at Publisher · View at Google Scholar · View at Scopus
  129. I. Rubinstein, B. Kumar, and C. Schriever, “Long-term montelukast therapy in moderate to severe COPD—a preliminary observation,” Respiratory Medicine, vol. 98, no. 2, pp. 134–138, 2004. View at Publisher · View at Google Scholar · View at Scopus
  130. N. Gueli, W. Verrusio, A. Linguanti et al., “Montelukast therapy and psychological distress in chronic obstructive pulmonary disease (COPD): a preliminary report,” Archives of Gerontology and Geriatrics, vol. 52, no. 1, pp. e36–e39, 2011. View at Publisher · View at Google Scholar · View at Scopus
  131. I. E. Zühlke, F. Kanniess, K. Richter et al., “Montelukast attenuates the airway response to hypertonic saline in moderate-to-severe COPD,” European Respiratory Journal, vol. 22, no. 6, pp. 926–930, 2003. View at Google Scholar · View at Scopus
  132. M. Cazzola, B. Boveri, P. Carlucci et al., “Lung function improvement in smokers suffering from COPD with zafirlukast, a CysLT1-receptor antagonist,” Pulmonary Pharmacology & Therapeutics, vol. 13, no. 6, pp. 301–305, 2000. View at Publisher · View at Google Scholar · View at Scopus
  133. L. J. Nannini Jr. and D. M. Flores, “Bronchodilator effect of zafirlukast in subjects with chronic obstructive pulmonary disease,” Pulmonary Pharmacology & Therapeutics, vol. 16, no. 5, pp. 307–311, 2003. View at Publisher · View at Google Scholar · View at Scopus
  134. A. P. Monteiro, E. Soledade, C. S. Pinheiro et al., “Pivotal role of 5-lipoxygenase pathway in lung injury after experimental sepsis,” American Journal of Respiratory Cell and Molecular Biology, vol. 50, no. 1, pp. 87–95, 2014. View at Google Scholar
  135. M. A. Kovach and T. J. Standiford, “The function of neutrophils in sepsis,” Current Opinion in Infectious Diseases, vol. 25, no. 3, pp. 321–327, 2012. View at Publisher · View at Google Scholar · View at Scopus
  136. N. de Maeyer, A.-M. Kochuyt, W. van Moerkercke, and M. Hiele, “Montelukast as a treatment modality for eosinophilic gastroenteritis,” Acta Gastro-Enterologica Belgica, vol. 74, no. 4, pp. 570–575, 2011. View at Google Scholar · View at Scopus
  137. G. Riccioni, C. di Ilio, P. Conti, T. C. Theoharides, and N. D'Orazio, “Advances in therapy with antileukotriene drugs,” Annals of Clinical and Laboratory Science, vol. 34, no. 4, pp. 379–387, 2004. View at Google Scholar · View at Scopus
  138. A. di Gennaro and J. Z. Haeggström, “The leukotrienes: immune-modulating lipid mediators of disease,” Advances in Immunology, vol. 116, pp. 51–92, 2012. View at Publisher · View at Google Scholar · View at Scopus
  139. S. O. Simons and M. H. Reijers, “Montelukast for bronchiolitis Obliterans syndrome after lung transplantation,” Chest, vol. 141, no. 1, pp. 275–276, 2012. View at Publisher · View at Google Scholar · View at Scopus
  140. F. G. Al-amran, N. R. Hadi, and A. M. Hashim, “Cysteinyl leukotriene receptor antagonist montelukast ameliorates acute lung injury following haemorrhagic shock in rats,” European Journal of Cardio-Thoracic Surgery, vol. 43, no. 2, pp. 421–427, 2013. View at Publisher · View at Google Scholar · View at Scopus
  141. S. I. Ochkur, C. A. Protheroe, W. Li et al., “Cys-leuktrienes promote fibrosis in a mouse model of eosinophil-mediated respiratory inflammation,” American Journal of Respiratory Cell and Molecular Biology, vol. 49, no. 6, pp. 1074–1084, 2013. View at Google Scholar
  142. I. Stelmach, A. Korzeniewska, W. Stelmach, P. Majak, T. Grzelewski, and J. Jerzynska, “Effects of montelukast treatment on clinical and inflammatory variables in patients with cystic fibrosis,” Annals of Allergy, Asthma & Immunology, vol. 95, no. 4, pp. 372–380, 2005. View at Google Scholar · View at Scopus
  143. C. Shimbori, N. Shiota, and H. Okunishi, “Pranlukast, a cysteinyl leukotriene type 1 receptor antagonist, attenuates the progression but not the onset of silica-induced pulmonary fibrosis in mice,” International Archives of Allergy and Immunology, vol. 158, no. 3, pp. 241–251, 2012. View at Publisher · View at Google Scholar · View at Scopus
  144. E. Fireman, “A silica-induced pulmonary fibrosis model: are we closer to `real life'?” International Archives of Allergy and Immunology, vol. 158, no. 3, pp. 211–212, 2012. View at Publisher · View at Google Scholar · View at Scopus
  145. J. Kato, T. Kohyama, H. Okazaki et al., “Leukotriene D4 potentiates fibronectin-induced migration of human lung fibroblasts,” Clinical Immunology, vol. 117, no. 2, pp. 177–181, 2005. View at Publisher · View at Google Scholar · View at Scopus
  146. M. Abe, S. Hashimoto, and H. Hara, “A case of diffuse panbronchiolitis effectively treated with low-dose macrolide antibiotics and leukotriene D4/E4 receptor antagonist,” Respiratory Medicine, vol. 92, no. 8, pp. 1084–1086, 1998. View at Publisher · View at Google Scholar · View at Scopus
  147. P. Drakatos, D. Lykouras, F. Sampsonas, K. Karkoulias, and K. Spiropoulos, “Targeting leukotrienes for the treatment of COPD?” Inflammation & Allergy: Drug Targets, vol. 8, no. 4, pp. 297–306, 2009. View at Publisher · View at Google Scholar · View at Scopus
  148. J. A. Corless and C. J. Warburton, “Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasis,” Cochrane Database of Systematic Reviews, no. 4, p. CD002174, 2000. View at Google Scholar · View at Scopus
  149. M. Remedios, D. Jones, and P. Kerlin, “Eosinophilic oesophagitis: epidemiology, pathogenesis and management,” Drugs, vol. 71, no. 5, pp. 527–540, 2011. View at Publisher · View at Google Scholar · View at Scopus
  150. C. J. Steib, M. Bilzer, M. op den Winkel et al., “Treatment with the leukotriene inhibitor montelukast for 10 days attenuates portal hypertension in rat liver cirrhosis,” Hepatology, vol. 51, no. 6, pp. 2086–2096, 2010. View at Publisher · View at Google Scholar · View at Scopus
  151. Y. Hattori, T. Ohno, T. Ae et al., “Gastric mucosal protection against ethanol by EP2 and EP 4 signaling through the inhibition of leukotriene C4 production,” American Journal of Physiology: Gastrointestinal and Liver Physiology, vol. 294, no. 1, pp. G80–G87, 2007. View at Publisher · View at Google Scholar · View at Scopus
  152. S. Miyaguchi, M. Oda, H. Saito, and H. Ishii, “Novel therapeutic approach to primary biliary cirrhosis patients: anti-eosinophil strategy,” Hepato-Gastroenterology, vol. 45, no. 23, pp. 1457–1461, 1998. View at Google Scholar · View at Scopus
  153. H. Nishio, Y. Hayashi, S. Terashima, and K. Takeuchi, “Protective effect of pranlukast, a cysteinyl-leukotriene receptor 1 antagonist, on indomethacin-induced small intestinal damage in rats,” Inflammopharmacology, vol. 15, no. 6, pp. 266–272, 2007. View at Publisher · View at Google Scholar · View at Scopus
  154. G. L. Capella, “Anti-leukotriene drugs in the prevention and treatment of hepatorenal syndrome,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 68, no. 4, pp. 263–265, 2003. View at Publisher · View at Google Scholar · View at Scopus
  155. S.-S. Tang, X.-Y. Wang, H. Hong et al., “Leukotriene D4 induces cognitive impairment through enhancement of CysLT1R-mediated amyloid-β generation in mice,” Neuropharmacology, vol. 65, pp. 182–192, 2013. View at Publisher · View at Google Scholar · View at Scopus
  156. X. Y. Wang, S. S. Tang, M. Hu et al., “Leukotriene D4 induces amyloid-β generation via CysLT 1R-mediated NF-κB pathways in primary neurons,” Neurochemistry International, vol. 62, no. 3, pp. 340–347, 2013. View at Publisher · View at Google Scholar · View at Scopus
  157. Y. Takahashi, K. Imai, H. Ikeda, Y. Kubota, E. Yamazaki, and F. Susa, “Open study of pranlukast add-on therapy in intractable partial epilepsy,” Brain & Development, vol. 35, no. 3, pp. 236–244, 2013. View at Publisher · View at Google Scholar · View at Scopus
  158. Q.-J. Shi, L. Xiao, B. Zhao et al., “Intracerebroventricular injection of HAMI 3379, a selective cysteinyl leukotriene receptor 2 antagonist, protects against acute brain injury after focal cerebral ischemia in rats,” Brain Research, vol. 1484, pp. 57–67, 2012. View at Publisher · View at Google Scholar · View at Scopus
  159. S. H. Fang, E. Q. Wei, Y. Zhou et al., “Increased expression of cysteinyl leukotriene receptor-1 in the brain mediates neuronal damage and astrogliosis after focal cerebral ischemia in rats,” Neuroscience, vol. 140, no. 3, pp. 969–979, 2006. View at Publisher · View at Google Scholar · View at Scopus
  160. X.-D. Qian, E.-Q. Wei, L. Zhang et al., “Pranlukast, a cysteinyl leukotriene receptor 1 antagonist, protects mice against brain cold injury,” European Journal of Pharmacology, vol. 549, no. 1–3, pp. 35–40, 2006. View at Publisher · View at Google Scholar · View at Scopus
  161. L. Wang, C. Du, J. Lv, W. Wei, Y. Cui, and X. Xie, “Antiasthmatic drugs targeting the cysteinyl leukotriene receptor 1 alleviate central nervous system inflammatory cell infiltration and pathogenesis of experimental autoimmune encephalomyelitis,” The Journal of Immunology, vol. 187, no. 5, pp. 2336–2345, 2011. View at Publisher · View at Google Scholar · View at Scopus
  162. H. Holme and L. C. Winckworth, “Montelukast can reduce the severity and extent of atopic dermatitis,” Journal of Paediatrics and Child Health, vol. 49, no. 5, pp. 412–415, 2013. View at Publisher · View at Google Scholar · View at Scopus
  163. M. Kosnik and T. Subic, “Add-on montelukast in antihistamine-resistant chronic idiopathic urticaria,” Respiratory Medicine, vol. 105, no. 1, pp. S84–S88, 2011. View at Publisher · View at Google Scholar · View at Scopus
  164. A. Zemtsov and S. Ali-Moncada, “Leukotriene inhibitor may be effective in treatment of psoriasis,” Acta Dermato-Venereologica, vol. 80, no. 5, p. 389, 2000. View at Google Scholar · View at Scopus
  165. A. Zemtsov, S. Bucchino, and M. R. McDowell, “Potential use of leukotriene inhibitors in treatment of psoriasis,” Dermatology, vol. 206, no. 2, pp. 179–180, 2003. View at Publisher · View at Google Scholar · View at Scopus
  166. E. Nobili, M. D. Salvado, L. Folkersen et al., “Cysteinyl leukotriene signaling aggravates myocardial hypoxia in experimental atherosclerotic heart disease,” PLoS ONE, vol. 7, no. 7, Article ID e41786, 2012. View at Publisher · View at Google Scholar · View at Scopus
  167. P. J. Turner, A. S. Kemp, M. Rogers, and S. Mehr, “Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis,” Pediatric Dermatology, vol. 29, no. 2, pp. 222–223, 2012. View at Publisher · View at Google Scholar · View at Scopus
  168. D. Yoshikawa and F. Goto, “Effect of platelet-activating factor antagonist and leukotriene antagonist on endotoxin shock in the rat: role of the leukocyte,” Circulatory Shock, vol. 38, no. 1, pp. 29–33, 1992. View at Google Scholar · View at Scopus
  169. V. Huerva, “Oral leukotriene antagonists in thyroid eye disease: myth or reality?” Ophthalmic Plastic & Reconstructive Surgery, vol. 27, no. 5, p. 398, 2011. View at Publisher · View at Google Scholar · View at Scopus
  170. S. Kuhle and M. S. Urschitz, “Anti-inflammatory medications for obstructive sleep apnea in children,” Cochrane Database of Systematic Reviews, vol. 1, p. CD007074, 2011. View at Google Scholar · View at Scopus
  171. M. Nozaki, M. Yoshikawa, K. Ishitani et al., “Cysteinyl leukotriene receptor antagonists inhibit tumor metastasis by inhibiting capillary permeability,” The Keio Journal of Medicine, vol. 59, no. 1, pp. 10–18, 2010. View at Publisher · View at Google Scholar · View at Scopus
  172. N. Tada, M. Furukawa, M. Ogura et al., “Experimental otitis media with effusion induced by leukotriene D4,” Auris Nasus Larynx, vol. 29, no. 2, pp. 127–132, 2002. View at Publisher · View at Google Scholar · View at Scopus
  173. S. Sapountzis, J. H. Kim, D. Francescato Veiga, and L. Masako Ferreira, “The effect of zafirlukast on capsule formation in post-radiation silicone implants,” Medical Hypotheses, vol. 78, no. 6, pp. 787–789, 2012. View at Publisher · View at Google Scholar · View at Scopus
  174. D. Goldmeier, P. Madden, M. McKenna, and N. Tamm, “Treatment of category III A prostatitis with zafirlukast: a randomized controlled feasibility study,” International Journal of STD & AIDS, vol. 16, no. 3, pp. 196–200, 2005. View at Publisher · View at Google Scholar · View at Scopus
  175. D. J. White, A. Vanthuyne, P. M. Wood, and J. G. Ayres, “Zafirlukast for severe recurrent vulvovaginal candidiasis: an open label pilot study,” Sexually Transmitted Infections, vol. 80, no. 3, pp. 219–222, 2004. View at Publisher · View at Google Scholar · View at Scopus